Blog
Article
This blog is the first in a two-part series on value-based care transformation, focusing on new site of care settings like patients' homes.

This blog is the first in a two-part series on value-based care transformation.
On March 4, 2022, ACCC President David R. Penberthy, MD, MBA, medical director of radiation oncology at Bon Secours Southside Medical Center in Petersburg, Va., announced his 2022-2023 President’s Theme: "Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience.” Work will focus on the equitable use of data and digital health tools to reduce disparities in care, as well as technology-based strategies to mitigate oncology workforce shortages and improve efficiencies in care delivery.
This theme was woven throughout the April 6 ACCC workshop, “Remaining Focused on Value-Based Care Transformation,” one of many resources under the Association’s Alternative Payment Model Coalition, which seeks to help cancer programs and practices continue their journey toward value-based cancer care delivery. With the Oncology Care Model (OCM) ending in June and no replacement program in sight, cancer programs and practices are looking to alternative care settings—including patients’ homes—and diversified service offerings to strengthen their bottom line.
Re-Evaluating Sites of Care
When the OCM ends, so do the MEOS (Monthly Enhanced Oncology Services) payments that many cancer programs and practices use to fund processes and services that support value-based care. Now, leaders will need to develop and implement creative strategies to offset this financial loss. Mount Sinai Health System in New York City looks to optimize its oncology care settings as one key strategy. Mark Liu, MHA, director of Strategic Initiatives at Mount Sinai Health System, talked about the integrated care settings the health system has created, including:
You can learn more about Mount Sinai Health System’s strategies for continuing value-based care by registering for and watching the on-demand workshop recording.
Read part two of this blog series here. This resource was made possible through the ACCC Alternative Payment Model Coalition that is supported by Merck & Co, Inc, and Takeda Oncology.